Scarica l'app Stockscreener
1.67
5.11%
-0.09
Dopo l'orario di chiusura:
1.66
-0.01
-0.60%
Precedente Chiudi:
$1.76
Aprire:
$1.77
Volume 24 ore:
656.76K
Relative Volume:
1.03
Capitalizzazione di mercato:
$76.37M
Reddito:
$19.94M
Utile/perdita netta:
$-37.37M
Rapporto P/E:
-1.6058
EPS:
-1.04
Flusso di cassa netto:
$-33.38M
1 W Prestazione:
-6.18%
1M Prestazione:
+15.17%
6M Prestazione:
+96.93%
1 anno Prestazione:
-18.93%
Intervallo 1D:
$1.65
$1.83
Intervallo di 1 settimana:
$1.56
$1.85
Portata 52W:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Nome
Werewolf Therapeutics Inc
Settore
Industria
Telefono
617-952-0555
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Confronta HOWL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.67 | 76.37M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-24 | Iniziato | Wedbush | Outperform |
| 2023-06-06 | Ripresa | Jefferies | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-25 | Iniziato | Evercore ISI | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-25 | Iniziato | Jefferies | Buy |
| 2021-05-25 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsJuly 2025 Outlook & Reliable Intraday Trade Plans - newser.com
Using data tools to time your Werewolf Therapeutics Inc. exitTrade Analysis Summary & Capital Efficiency Focused Strategies - newser.com
Identifying reversal signals in Werewolf Therapeutics Inc.2025 Risk Factors & Intraday High Probability Alerts - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - newser.com
Werewolf Therapeutics Inc. stock trendline breakdown2025 Volatility Report & Free Expert Verified Stock Movement Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesSwing Trade & Reliable Volume Spike Alerts - newser.com
How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Yahoo Finance
Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Werewolf Therapeutics Inc Azioni (HOWL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 14 '25 |
Buy |
0.98 |
162,539 |
159,288 |
6,237,482 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 13 '25 |
Buy |
0.98 |
52,974 |
51,915 |
6,074,943 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
1,963 |
2,061 |
3,208,793 |
| EVNIN LUKE | Director |
Mar 27 '25 |
Sale |
1.05 |
2,425 |
2,546 |
4,309,860 |
| GADICKE ANSBERT | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
4,386 |
4,605 |
6,718,670 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):